US 12,298,315 B2
Systems and methods to identify and treat subjects at risk for obstetrical complications
Tinnakorn Chaiworapongsa, Grosse Pointe Park, MI (US); Roberto Romero, Grosse Pointe, MI (US); and Sonia S. Hassan, Novi, MI (US)
Assigned to Wayne State University, Detroit, MI (US); and The United States of America as Represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed by Wayne State University, Detroit, MI (US); and The United States of America as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on May 10, 2023, as Appl. No. 18/315,230.
Application 16/387,486 is a division of application No. 15/129,771, granted, now 10,281,475, issued on May 7, 2019, previously published as PCT/US2015/023117, filed on Mar. 27, 2015.
Application 18/315,230 is a continuation of application No. 16/387,486, filed on Apr. 17, 2019, granted, now 11,686,735.
Claims priority of provisional application 61/971,486, filed on Mar. 27, 2014.
Prior Publication US 2023/0341414 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); A61K 31/22 (2006.01); A61K 31/616 (2006.01); A61K 31/727 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G16H 50/30 (2018.01)
CPC G01N 33/689 (2013.01) [A61K 31/22 (2013.01); A61K 31/616 (2013.01); A61K 31/727 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6872 (2013.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G16H 50/30 (2018.01); C12Q 2600/158 (2013.01); G01N 2333/475 (2013.01); G01N 2333/912 (2013.01); G01N 2800/368 (2013.01); G01N 2800/50 (2013.01)] 14 Claims
 
1. A method of treating an imbalance of angiogenic factor(s) and anti-angiogenic factor(s) in a pregnant female human subject, comprising;
identifying the subject as having or at risk of the imbalance of angiogenic factors and anti-angiogenic factors, wherein the angiogenic factors comprise placental growth factor (PIGF), and/or the anti-angiogenic factors comprise soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and/or soluble endoglin (sEng); and
administering to the subject an effective amount of a water-soluble statin, thereby treating the imbalance of angiogenic factors and anti-angiogenic factors.